INNOVACAP

Innova Captab Share Price

₹966.00 +34.25 (3.68%)

21 Nov, 2024 14:48

SIP TrendupStart SIP in INNOVACAP

Start SIP

Performance

  • Low
  • ₹905
  • High
  • ₹974
  • 52 Week Low
  • ₹421
  • 52 Week High
  • ₹1,019
  • Open Price₹935
  • Previous Close₹932
  • Volume89,095

Investment Returns

  • Over 1 Month + 28.83%
  • Over 3 Month + 37.43%
  • Over 6 Month + 85.43%
  • Over 1 Year + 114.53%
SIP Lightning

Smart Investing Starts Here Start SIP with Innova Captab for Steady Growth!

Invest Now

Innova Captab Fundamentals Fundamentals refer to the financial data that companies report on a quarterly or annual basis.

  • P/E Ratio
  • 46.7
  • PEG Ratio
  • 0.9
  • Market Cap Cr
  • 5,528
  • P/B Ratio
  • 6.7
  • Average True Range
  • 49.44
  • EPS
  • 20.68
  • Dividend Yield
  • 0
  • MACD Signal
  • 46.3
  • RSI
  • 65.98
  • MFI
  • 86.6

Innova Captab Financials

Innova Captab Technicals

EMA & SMA

Current Price
₹966.00
+ 34.25 (3.68%)
pointer
  • stock-down_img
  • Bullish Moving Average 15
  • stock-up_img
  • Bearish Moving Average 1
  • 20 Day
  • ₹866.21
  • 50 Day
  • ₹791.65
  • 100 Day
  • ₹719.93
  • 200 Day
  • ₹615.99

Resistance and Support

940.85 Pivot Speed
  • R3 1,013.40
  • R2 992.25
  • R1 962.00
  • S1 910.60
  • S2 889.45
  • S3 859.20

What's your outlook on Innova Captab?

You can only vote for once

Ratings

Master Rating

EPS Strenth

Price Strength

Buyer Demand

Group Rank

Innova Captab Ltd. is a leading pharmaceutical company in India, specializing in the manufacturing of formulations, including tablets, capsules, and syrups. It caters to domestic and international markets with a focus on quality and innovation.

Innova Captab Ltd has an operating revenue of Rs. 1,177.59 Cr. on a trailing 12-month basis. An annual revenue growth of 17% is outstanding, Pre-tax margin of 12% is healthy, ROE of 11% is good. The company has a reasonable debt to equity of 25%, which signals a healthy balance sheet. The stock from a technical standpoint is comfortably placed above its key moving averages, around 18% and 56% from 50DMA and 200DMA. It has recently broken out of a base in its weekly chart and is trading around 10% from the pivot point (which is extended from the ideal buying range for a stock). From an O'Neil Methodology perspective, the stock has an EPS Rank of 44 which is a POOR score indicating inconsistency in earnings, a RS Rating of 87 which is GOOD indicating the outperformance as compared to other stocks, Buyer Demand at A which is evident from recent demand for the stock, Group Rank of 39 indicates it belongs to a strong industry group of Medical-Diversified and a Master Score of B is close to being the best. Institutional holding has gone up in the last reported quarter is a positive sign. Overall, the stock is lagging behind in earnings parameter, but excellent technical strength makes it a stock to examine in more detail.

Disclaimer: This stock analysis report is algorithmically generated for informational purposes only and should not be considered as a buy or sell recommendation.

View More

Innova Captab Corporate Actions - Bonus, Splits, Dividends

Date Purpose Remarks
2024-11-07 Quarterly Results
2024-08-09 Quarterly Results
2024-05-29 Audited Results
2024-02-13 Quarterly Results
2024-01-18 Quarterly Results

Innova Captab F&O

Innova Captab Shareholding Pattern

50.9%
11.37%
1.89%
1.01%
0%
26%
8.83%

About Innova Captab

  • NSE Symbol
  • INNOVACAP
  • BSE Symbol
  • 544067
  • Managing Director
  • Mr. Vinay Kumar Lohariwala
  • ISIN
  • INE0DUT01020

Similar Stocks to Innova Captab

Innova Captab FAQs

Innova Captab share price is ₹966 As on 21 November, 2024 | 14:34

The Market Cap of Innova Captab is ₹5527.9 Cr As on 21 November, 2024 | 14:34

The P/E ratio of Innova Captab is 46.7 As on 21 November, 2024 | 14:34

The PB ratio of Innova Captab is 6.7 As on 21 November, 2024 | 14:34

Open Free Demat Account

Be a part of 5paisa community - The first listed discount broker of India.

+91
 
footer_form

Disclaimer: Investment in securities market are subject to market risks, read all the related documents carefully before investing. For detailed disclaimer please Click here.

Q2FY23